Related Experiment Video
Updated: Jun 13, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Barriers and opportunities in pancreatic cancer immunotherapy
Yixin Ju1,2, Dongzhi Xu1,2, Miao-Miao Liao1
1Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple cancers, has yet to demonstrate significant benefits in PDAC. Recent studies have revealed the immunosuppressive characteristics of the PDAC tumor microenvironment (TME), including immune cells with suppressive properties, desmoplastic stroma, microbiome influences, and PDAC-specific signaling pathways. In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, TME differences among various mouse models of pancreatic cancer, and the mechanisms underlying resistance to immunotherapeutic interventions. Furthermore, we discuss the potential of targeting cancer cell-intrinsic pathways and TME components to sensitize PDAC to immune therapies, providing insights into strategies and future perspectives to break through the barriers in improving pancreatic cancer treatment.
Insights
Pancreatic cancer (PDAC) is difficult to treat due to its immunosuppressive tumor microenvironment (TME). Targeting TME components and cancer pathways may improve immunotherapy effectiveness for pancreatic cancer.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to late diagnosis and limited treatment options.
- Immunotherapy has shown limited success in PDAC compared to other cancers.
- The PDAC tumor microenvironment (TME) is characterized by immunosuppressive factors, including specific immune cells, stromal components, and signaling pathways.
Purpose of the Study:
- To review recent advancements in understanding the immunosuppressive PDAC TME.
- To explore differences in TME across various pancreatic cancer mouse models.
- To discuss mechanisms of resistance to immunotherapy in PDAC and strategies to overcome them.
Main Methods:
- Literature review of recent studies on PDAC TME and immunotherapy.
- Analysis of TME characteristics in different pancreatic cancer models.
- Discussion of intrinsic cancer cell pathways and TME components as therapeutic targets.
Main Results:
- The PDAC TME exhibits significant immunosuppressive properties.
- Variations in TME exist among different preclinical models of pancreatic cancer.
- Mechanisms of immunotherapy resistance in PDAC are multifaceted, involving both cellular and stromal components.
Conclusions:
- Understanding the PDAC TME is crucial for developing effective immunotherapies.
- Targeting cancer-intrinsic pathways and TME components holds promise for sensitizing PDAC to immune therapies.
- Future strategies should focus on overcoming TME-mediated resistance to improve pancreatic cancer treatment outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...